McDermott + Bull has successfully placed Steven Cha as the Chief Medical Officer at NKMax America, Inc. Steven will provide leadership and direction for the company’s pipeline of clinical development programs in cellular therapy. He will be a key member of the senior management team and will serve on the executive committee, which determines and oversees the company’s clinical research and development and sets the overall strategic direction of the organization.
Steven is a Stanford-trained hematologist and possesses a strong background in clinical leadership, with deep oncology knowledge and extensive clinical development experience. He has been classically trained by industry-leading companies like Amgen, Allergan, and Pfizer and has a fellowship from Stanford University. Most recently, he served as Vice President of Oncology at Samumed, LLC and has a proven track record of successfully building clinical development teams in medical affairs and clinical operations. He received his Bachelor of Science in biochemistry and cell biology at the University of California, San Diego and a master’s degree at Tufts University School of Medicine.
NKMax harnesses the power of the body’s immune system through the development of unique natural killer (NK) cell therapies. NKMax’s U.S. headquarters is a newly constructed state-of-the-art cGMP cell therapy manufacturing facility. At 25,000-square-feet, it is home to their growing U.S. team and includes a CAP/CLIA certified laboratory, enabling NKMax to manufacture clinical and commercial NK cell therapies.
This executive search was completed by McDermott + Bull Co-Founder and Managing Partner Chris Bull, Managing Director Ken Dropiewski, Director Anne Terry, and Senior Executive Recruiters Quyen Doan and Sara Pizarro.